Nucleic acid molecules encoding anti-CD27 antibodies

Patent metadata

Field	Value
Publication number	US-9683046-B2
Application number	US-201514790144-A
Country	US
Kind code	B2
Filing date	Jul 2, 2015
Priority date	Mar 15, 2012
Publication date	Jun 20, 2017
Grant date	Jun 20, 2017

Abstract

Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.

First claim

What is claimed:

1. An isolated nucleic acid molecule, selected from the group consisting of (i) the light chain nucleotide sequence of SEQ ID NO: 163 and/or the heavy chain nucleotide sequence of SEQ ID NO: 164; (ii) a nucleotide sequence encoding the light chain variable region amino acid sequence of SEQ ID NO: 143 and/or a nucleotide sequence encoding the heavy chain variable region amino acid sequence of SEQ ID NO: 133; (iii) a nucleotide sequence encoding the light chain variable region amino acid sequence of SEQ ID NO: 127 and/or a nucleotide sequence encoding the heavy chain variable region amino acid sequence of SEQ ID NO: 126; (iv) a nucleotide sequence encoding the light chain variable region amino acid sequence selected from the group consisting of SEQ ID NOs: 137-144 and 148 and/or a nucleotide sequence encoding the heavy chain variable region amino acid sequence selected from the group consisting of SEQ ID NOs: 128-136 and 145-147; and (v) a nucleotide sequence encoding the light chain variable region amino acid sequence of SEQ ID NO: 143, a nucleotide sequence encoding the heavy chain variable region amino acid sequence of SEQ ID NO: 133, a nucleotide sequence encoding the IgG4 heavy chain constant region amino acid sequence of SEQ ID NO: 159, and a nucleotide sequence encoding the IgG4 light chain constant region amino acid sequence of SEQ ID NO: 160.

2. An isolated nucleic acid vector or vectors comprising the isolated nucleic acid molecule of claim 1 .

3. A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid vector or vectors of claim 2 .

4. The host cell according to claim 3 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

5. A method for producing an anti-CD27 antibody, comprising incorporating the nucleic acid molecule of claim 1 into a vector, transforming a host cell, transgenic animal or transgenic plant to express an antibody and recovering the expressed antibody.

6. An isolated nucleic acid molecule, comprising a nucleotide or nucleotides encoding an light chain variable region and an antibody heavy chain variable region, said light chain variable region comprising a complementarity determining region light chain 1 (CDRL1) amino acid sequence selected from the group consisting of SEQ ID NOs: 59-66 and 158, a CDRL2 amino acid sequence selected from the group consisting of SEQ ID NOs: 67-74, a CDRL3 amino acid sequence of SEQ ID NO: 75, said heavy chain variable region comprising a CDRH1 amino acid sequence selected from the group consisting of SEQ ID NOs: 42-45 and 161, a CDRH2 amino acid sequence selected from the group consisting of SEQ ID NOs: 46-57, 156, and 157; and a CDRH3 amino acid sequence of SEQ ID NO: 58.

7. An isolated nucleic acid vector or vectors comprising the isolated nucleic acid molecule of claim 6 .

8. A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid vector or vectors of claim 7 .

9. The host cell according to claim 8 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

10. A method for producing an anti-CD27 antibody, comprising incorporating the nucleic acid molecule of claim 6 into a vector, transforming a host cell, transgenic animal or transgenic plant to express an antibody and recovering the expressed antibody.

11. An isolated nucleic acid molecule, comprising a nucleotide or nucleotides encoding an light chain variable region and an antibody heavy chain variable region, said light chain variable region comprising a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO: 62, a CDRL2 amino acid sequence of SEQ ID NO: 68, a CDRL3 amino acid sequence of SEQ ID NO: 75, said heavy chain variable region comprising a CDRH1 amino acid sequence selected from the group consisting of SEQ ID NOs: 44 and 161, a CDRH2 amino acid sequence of SEQ ID NO: 47; and a CDRH3 amino acid sequence of SEQ ID NO: 58.

12. An isolated nucleic acid vector or vectors comprising the isolated nucleic acid molecule of claim 11 .

13. A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid vector or vectors of claim 12 .

14. The host cell according to claim 13 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

15. A method for producing an anti-CD27 antibody, comprising incorporating the nucleic acid molecule of claim 11 into a vector, transforming a host cell, transgenic animal or transgenic plant to express an antibody and recovering the expressed antibody.

16. An isolated nucleic acid molecule, comprising a nucleotide or nucleotides encoding an light chain variable region and an antibody heavy chain variable region, said light chain variable region comprising a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO: 59, a CDRL2 amino acid sequence of SEQ ID NO: 67, a CDRL3 amino acid sequence of SEQ ID NO: 75, said heavy chain variable region comprising a CDRH1 amino acid sequence of SEQ ID NO: 42, a CDRH2 amino acid sequence of SEQ ID NO: 46; and a CDRH3 amino acid sequence of SEQ ID NO: 58.

17. An isolated nucleic acid vector or vectors comprising the isolated nucleic acid molecule of claim 16 .

18. A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid vector or vectors of claim 17 .

19. The host cell according to claim 18 , wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

20. A method for producing an anti-CD27 antibody, comprising incorporating the nucleic acid molecule of claim 16 into a vector, transforming a host cell, transgenic animal or transgenic plant to express an antibody and recovering the expressed antibody.

Assignees

• Janssen Biotech Inc

Inventors

• Chen John
• Fransson Johan
• Fursov Natalie
• Hamel Damon
• Malia Thomas
• Obmolova Galina
• Ort Tatiana
• Rycyzyn Michael
• Scully Michael
• Sweet Raymond
• Teplyakov Alexey
• Wheeler John
• Almagro Juan Carlos

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title